SCHOLAR ROCK HOLDING CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.41 USD | +1.33% |
|
-11.11% | -55.32% |
Presenter SpeechJay Backstrom (Executives)Scholar Rock and pleasure to be here at the Goldman ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company to develop a proprietary platform for the development of monoclonal antibodies that locally and selectively target the precursor. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as the first muscle-targeted therapy for the treatment of spinal muscular atrophy (SMA). Its other product candidate, SRK-181, a selective inhibitor of the activation of latent TGFb, is being developed for the treatment of cancers.
Calendar
27/06/2024
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.3
USD
Average target price
26.5
USD
Spread / Average Target
+219.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -55.32% | 662M | |
| +15.60% | 122B | |
| +20.39% | 113B | |
| +8.24% | 22.84B | |
| -20.23% | 20.72B | |
| -16.19% | 16.51B | |
| -13.77% | 16.39B | |
| -44.35% | 15.83B | |
| +2.35% | 13.49B | |
| +66.40% | 11.67B |
- Stock Market
- Equities
- SRRK Stock
- News Scholar Rock Holding Corporation
- Transcript : Scholar Rock Holding Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-13-2024 09
